Harvard Bioscience (HBIO) Gross Margin (2010 - 2026)
Harvard Bioscience (HBIO) reported Gross Margin of 58.99% for Q1 2026, up 304.0% year-over-year from 14.6% in Q1 2025, and down 1.2% quarter-over-quarter from 59.71% in Q4 2025.
Harvard Bioscience (HBIO) Gross Margin (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Gross Margin data on file, last reported at 58.99% in Q1 2026.
- Gross Margin for Q1 2026 came in at 58.99%, up 304.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.42% (up 133.0% YoY), and the FY2025 annual result was 57.67%, down 51.0% from the prior year.
- Gross Margin retreated to 58.99% in Q1 2026 per HBIO's latest filing, from 59.71% in the prior quarter.
- Over five years, Gross Margin peaked at 61.2% in Q1 2023 and troughed at 45.21% in Q3 2022.
- A 5-year average of 57.14% and a median of 57.97% in 2023 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin tumbled 977 bps in 2022, then soared 1285 bps in 2023.
- A 5-year view of Gross Margin shows it stood at 55.7% in 2022, then gained by 4 bps to 57.99% in 2023, then dropped by 2 bps to 57.06% in 2024, then increased by 5 bps to 59.71% in 2025, then dropped by 1 bps to 58.99% in 2026.
- Business Quant data shows HBIO's Gross Margin at 58.99% in Q1 2026, 59.71% in Q4 2025, and 58.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 66.06% |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 45.69% |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 25.04% |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 62.25% |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 35.08% |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 54.66% |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 68.00% |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 70.82% |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 32.99% |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | 58.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.99% |
| Dec 31, 2025 | 59.71% |
| Sep 30, 2025 | 58.38% |
| Jun 30, 2025 | 56.40% |
| Mar 31, 2025 | 55.96% |
| Dec 31, 2024 | 57.06% |
| Sep 30, 2024 | 58.10% |
| Jun 30, 2024 | 57.23% |
| Mar 31, 2024 | 60.26% |
| Dec 31, 2023 | 57.99% |
| Sep 30, 2023 | 58.06% |
| Jun 30, 2023 | 57.97% |
| Mar 31, 2023 | 61.20% |
| Dec 31, 2022 | 55.70% |
| Sep 30, 2022 | 45.21% |
| Jun 30, 2022 | 56.96% |
| Mar 31, 2022 | 56.21% |
| Dec 31, 2021 | 59.17% |
| Sep 30, 2021 | 54.98% |
| Jun 30, 2021 | 56.01% |